19. Cutler A., Durgam S., Wang Y. (2018) Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study. CNS Spectr, vol. 23, no 1, pp. 39-50.
20. Nasrallah H., Earley W., Cutler A. (2017) The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis. BMC Psychiatry, vol. 17, no 1, pp. 305.
21. Instrukciya po medicinskomu primeneniyu lekarstvennogo sredstva "Reagila" Available at: https://www.rceth.by/NDfiles/instr/10735_19_i.pdf (accessed 03 March 2020).
22. (2018) Instrukciya po primeneniyu analiz vliyaniya na byudzhet pri ocenke medicinskoj tekhnologii: utv. M-vom zdravoohraneniya Resp. Belarus' [Instructions for use analysis of the impact on the budget when evaluating medical technology: approved. Ministry of health of the Republic of Belarus]. Minsk: Resp. nauchno-prakticheskij centr medicinskih tekhnologij, informatizacii, upravleniya i ekonomiki zdravoohraneniya, Reg. nomer 244 - 1218. 10 p.
23. (2018) Instrukciya po primeneniyu opredelenie pryamyh nemedicinskih i kosvennyh zatrat pri ocenke medicinskoj tekhnologii: utv. M-vom zdravoohraneniya Resp. Belarus' [Instructions for use determination of direct non-medical and indirect costs approved. Ministry of health of the Republic of Belarus]. Minsk: Resp. nauchno-prakticheskij centr medicinskih tekhnologij, informatizacii, upravleniya i ekonomiki zdravoohraneniya, Reg. nomer 243 - 1218. 14 p.
24. (2018) Instrukciya po primeneniyu opredelenie pryamyh medicinskih zatrat pri kliniko-ekonomicheskom obosnovanii vnedreniya Klinicheskih protokolovi novyh metodov okazaniya medicinskojpomoshchi: utv. M-vom zdravoohraneniya Resp. Belarus' [Instructions for use determination of direct medical costs in the clinical and economic justification of the introduction of Clinical protocols and new methods of medical care UTV. Ministry of health of the Republic of Belarus]. Minsk: Resp. nauchno-prakticheskij centr medicinskih tekhnologij, informatizacii, upravleniya i ekonomiki zdravoohraneniya, Reg. nomer 245 - 1218. 18 p.
25. (2018) Instrukciya po primeneniyu opredelenie celevoj populyacii pacientov pri ocenke medicinskoj tekhnologii: utv. M-vom zdravoohraneniya Resp. Belarus' [Instructions for use determining the target patient population when evaluating medical technology: approved. Ministry of health of the Republic of Belarus]. Minsk: Resp. nauchno-prakticheskij centr medicinskih tekhnologij, informatizacii, upravleniya i ekonomiki zdravoohraneniya, Reg. nomer 246 - 1218. 10 p.
26. (2013) Federal'nye klinicheskie rekomendaciipo diagnostike i lecheniyu shizofrenii [Federal clinical guidelines for the diagnosis and treatment of schizophrenia]. Moskovskij nauchno-issledovatel'skij institut psihiatrii, Oktyabr, 41 p.
27. Rahimov K., Akimbaeva A., Zordinova K., (2010) Dokazatel'naya farmakoterapiya shizofrenii (kliniko-ekonomicheskie aspekty) [Evidual pharmacotherapy of schizophrenia (clinical and economic aspects)]. Modern problems of science and education, vol. 4, pp. 137-156.
28. (2019) Oficial'nyj statisticheskij sbornik [Health in the Republic of Belarus: officer. stat.]. Minsk, 261 p.
29. Bobes J., Arango C., Garcia-Garcia M. (2010) CLAMORS Study Collaborative Group. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study. J Clin Psychiatry, vol. 71, no 3, pp. 280-286.
30. Rabinowitz J., Werbeloff N., Caers I. (2013) Negative symptoms in schizophrenia-the remarkable impact of inclusion definitions in clinical trials and their consequences. SchizophrRes, vol. 150, no 2, pp. 334-338.
31. D'yakov I., Zyryanov S. (2019) Kliniko-ekonomicheskaya effektivnost'primeneniya Kariprazina pri shizofrenii [Clinical and economic effectiveness of cariprazine in schizophrenia]. Journal of Neurology and Psychiatry. S.S. Korsakova, vol. 119, no 7, pp. 83-91.